US biotech company Moderna on Monday announced that it plans to request an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA) after the final results from a late-stage study indicated its Covid-19 vaccine candidate is 94.1 per cent effective.

Moderna also said that its vaccine candidate had 100 per cent efficacy against severe disease. There were zero such COVID-19 cases among those vaccinated, but 30 in the placebo group.